Bukwang Pharmaceutical Co., Ltd. (003000.KS)
KRW 4745.0
(-1.35%)
KRW 4745.0
(-1.35%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 78.52 Billion KRW | 11315.53% |
| 2022 | 687.87 Million KRW | -38.26% |
| 2021 | 1.11 Billion KRW | -2.17% |
| 2020 | 1.13 Billion KRW | -30.71% |
| 2019 | 1.64 Billion KRW | 0.0% |
| 2018 | - KRW | 0.0% |
| 2017 | - KRW | 0.0% |
| 2016 | - KRW | 0.0% |
| 2015 | - KRW | 0.0% |
| 2014 | - KRW | 0.0% |
| 2013 | - KRW | 0.0% |
| 2012 | - KRW | -100.0% |
| 2011 | 40 Billion KRW | 0.0% |
| 2010 | - KRW | -100.0% |
| 2009 | 30 Billion KRW | 0.0% |
| 2008 | 30 Billion KRW | 0.0% |
| 2007 | - KRW | 0.0% |
| 2006 | - KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 78.74 Billion KRW | 0.15% |
| 2024 Q1 | 78.62 Billion KRW | 0.13% |
| 2023 Q2 | 600.16 Million KRW | -5.88% |
| 2023 FY | 78.52 Billion KRW | 11315.53% |
| 2023 Q4 | 78.52 Billion KRW | 156.99% |
| 2023 Q1 | 637.66 Million KRW | -7.3% |
| 2023 Q3 | 30.55 Billion KRW | 4991.23% |
| 2022 Q3 | 951 Million KRW | -9.24% |
| 2022 Q2 | 1.04 Billion KRW | 1.25% |
| 2022 Q1 | 1.03 Billion KRW | -7.12% |
| 2022 FY | 687.87 Million KRW | -38.26% |
| 2022 Q4 | 687.87 Million KRW | -27.67% |
| 2021 Q2 | 1.3 Billion KRW | 15.71% |
| 2021 FY | 1.11 Billion KRW | -2.17% |
| 2021 Q3 | 1.21 Billion KRW | -7.13% |
| 2021 Q4 | 1.11 Billion KRW | -8.18% |
| 2021 Q1 | 1.12 Billion KRW | -0.86% |
| 2020 FY | 1.13 Billion KRW | -30.71% |
| 2020 Q2 | 1.44 Billion KRW | -6.44% |
| 2020 Q3 | 1.37 Billion KRW | -5.01% |
| 2020 Q4 | 1.13 Billion KRW | -17.13% |
| 2020 Q1 | 1.54 Billion KRW | -5.91% |
| 2019 Q1 | 10.29 Million KRW | 0.0% |
| 2019 Q4 | 1.64 Billion KRW | 4590.38% |
| 2019 FY | 1.64 Billion KRW | 0.0% |
| 2019 Q2 | 10.71 Million KRW | 4.05% |
| 2019 Q3 | 35.04 Million KRW | 227.2% |
| 2018 Q1 | - KRW | 0.0% |
| 2018 FY | - KRW | 0.0% |
| 2018 Q4 | - KRW | 0.0% |
| 2018 Q3 | - KRW | 0.0% |
| 2018 Q2 | - KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2017 Q4 | - KRW | 0.0% |
| 2017 FY | - KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2016 Q4 | - KRW | 0.0% |
| 2016 FY | - KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2016 Q2 | - KRW | 0.0% |
| 2016 Q3 | - KRW | 0.0% |
| 2015 Q1 | - KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| 2015 Q4 | - KRW | 0.0% |
| 2015 Q3 | - KRW | 0.0% |
| 2015 Q2 | - KRW | 0.0% |
| 2014 Q4 | - KRW | 0.0% |
| 2014 FY | - KRW | 0.0% |
| 2014 Q2 | - KRW | 0.0% |
| 2014 Q3 | - KRW | 0.0% |
| 2013 Q4 | - KRW | 0.0% |
| 2013 FY | - KRW | 0.0% |
| 2013 Q1 | 10 Billion KRW | 0.0% |
| 2012 Q4 | - KRW | -100.0% |
| 2012 Q1 | 40 Billion KRW | 0.0% |
| 2012 FY | - KRW | -100.0% |
| 2012 Q2 | 40 Billion KRW | 0.0% |
| 2012 Q3 | 40 Billion KRW | 0.0% |
| 2011 FY | 40 Billion KRW | 0.0% |
| 2011 Q3 | - KRW | 0.0% |
| 2011 Q1 | - KRW | 0.0% |
| 2011 Q2 | - KRW | 0.0% |
| 2010 Q3 | - KRW | -100.0% |
| 2010 Q4 | - KRW | 0.0% |
| 2010 Q2 | 30 Billion KRW | 0.0% |
| 2010 Q1 | 30 Billion KRW | 0.0% |
| 2010 FY | - KRW | -100.0% |
| 2009 Q4 | 30 Billion KRW | 0.0% |
| 2009 Q3 | 30 Billion KRW | 0.0% |
| 2009 Q2 | 30 Billion KRW | 0.0% |
| 2009 FY | 30 Billion KRW | 0.0% |
| 2008 Q4 | 30 Billion KRW | 0.0% |
| 2008 Q2 | - KRW | 0.0% |
| 2008 Q3 | 30 Billion KRW | 0.0% |
| 2008 FY | 30 Billion KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q2 | - KRW | 0.0% |
| 2007 Q3 | - KRW | 0.0% |
| 2007 Q4 | - KRW | 0.0% |
| 2006 FY | - KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -475.695% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 61.138% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | -162.831% |
| HANDOK Inc. | 123.78 Billion KRW | 36.561% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -16405.794% |
| Yuhan Corporation | 60.23 Billion KRW | -30.367% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 51.525% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -77023.19% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 4.271% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -13202.373% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -1197.936% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -323.947% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -523.998% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -4811.363% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -475.695% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -65513.45% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 35.103% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | -145.391% |
| JW Holdings Corporation | 20.65 Billion KRW | -280.132% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -429.674% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | -161.75% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -161.75% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -35762.609% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -13423.75% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | -58.418% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -1663.815% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -475.695% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -312.689% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 15.94% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -161.75% |
| Yuhan Corporation | 60.23 Billion KRW | -30.367% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -647.858% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | -94.476% |
| Suheung Co., Ltd. | 74 Billion KRW | -6.105% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -161.75% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -1784.615% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -616.307% |
| CKD Bio Corp. | 69.43 Billion KRW | -13.098% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | -127.117% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -386.897% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -25473.534% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -35762.609% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | -8.893% |
| Boryung Corporation | 151.7 Billion KRW | 48.239% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -1197.936% |
| JW Lifescience Corporation | 168 Million KRW | -46641.147% |